Clinical trials suggest people eat fewer calories while on semaglutide, with many showing a reduced desire for high-fat meals
The density was calculated by dividing the amount of DCX-expressing cells with the area of the dentate gyrus for each section
Three FDA-approved GLP-1 medications are eligible under the bridge program when used to reduce excess body weight and maintain weight reduction: Wegovy (semaglutide), available as a weekly injection or daily oral tablet, manufactured by Novo Nordisk Zepbound (tirzepatide), available in the KwikPen autoinjector format, manufactured by Eli Lilly Foundayo (orforglipron), the first non-peptide, small-molecule oral GLP-1 for weight loss, recently FDA-approved and manufactured by Eli Lilly Each of these medications works by mimicking the activity of glucagon-like peptide-1, a hormone that regulates appetite, fullness, and blood sugar
In addition, mixing phentermine with alcohol may worsen withdrawal symptoms for those undergoing alcohol substance use disorder treatments, such as an inpatient detox program